Liver therapy (local classification)
ATC code: A05BA-ESSENTIALE (Essential phospholipids (local code))
The manufacturer claims restoration of hepatocyte cell membranes and normalization of lipid and protein metabolism in the liver. Active components are phosphatidylcholine and related phospholipids derived from soy. International liver disease guidelines (, ) do not mention essential phospholipids as a therapy with proven efficacy.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Guidelines for alcoholic liver disease (, ) do not mention essential phospholipids. Management relies on complete alcohol abstinence. In severe alcoholic hepatitis with a high Maddrey discriminant function, short courses of corticosteroids are indicated. Nutritional support and complication management are essential.
Not recommended
— Liver 'detox' and cleansing: 'Liver cleansing' or 'detox' as a clinical indication does not exist in international hepatology. The liver has its own detoxification systems (cytochrome P450 enzymes, phase II conjugation, transport systems) that do not require pharmacological 'support'. In liver injury, therapy targets the underlying cause, not 'general support' or 'cleansing'.
Not recommended
Clinical guidelines for MASLD ( 2024, 2023; the new term MASLD replaced NAFLD per the 2023 AASLD/EASL consensus, Rinella et al. Hepatology 2023) do not consider essential phospholipids a therapy with proven clinical efficacy. MASLD management rests on weight loss (minimum 7–10 % of baseline), physical activity, and metabolic risk factor control. In patients with T2D and MASLD, GLP-1 receptor agonists (semaglutide, liraglutide) and resmetirom (-approved in 2024 for MASH with fibrosis) have demonstrated benefit.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
No international recommendations on use in pregnancy.
Doctors in Russia and Eastern Europe prescribe essential phospholipids (Essentiale) for chronic hepatitis and steatohepatitis. The product has no AEMPS registration. Cochrane reviews do not confirm clinical benefit in hepatitis. The preparation contains phosphatidylcholine and looks plausibly safe by composition, but no randomised data exist on transfer into human milk or efficacy during breastfeeding. AEMPS does not back its use as a hepatoprotector in nursing mothers.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Essential phospholipids is evaluated for the following indications with varying evidence strength: Alcoholic liver disease (evidence tier F), Non-alcoholic fatty liver disease (evidence tier F), Body detoxification and cleansing (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Essential phospholipids (≥ 1 in 100): Per label — gastric discomfort, rarely diarrhea, Allergic skin reactions. See the Safety section for uncommon and serious reactions.
FDA category N. No international recommendations on use in pregnancy.
Doctors in Russia and Eastern Europe prescribe essential phospholipids (Essentiale) for chronic hepatitis and steatohepatitis. The product has no AEMPS registration. Cochrane reviews do not confirm clinical benefit in hepatitis. The preparation contains phosphatidylcholine and looks plausibly safe by composition, but no randomised data exist on transfer into human milk or efficacy during breastfeeding. AEMPS does not back its use as a hepatoprotector in nursing mothers.
Essential phospholipids is contraindicated in: Hypersensitivity to phosphatidylcholine, soy oil, or other components; Antiphospholipid syndrome (injectable form). Full list in the Safety section.
universal 'protectors' of the liver do not exist. The only truly effective strategy is to eliminate the causative factor (alcohol, toxin, hepatotropic virus, offending drug).
routine 'hepatoprotection' in patients with normal liver tests is not indicated. In drug-induced liver injury (for example, from antituberculosis drugs), management relies on discontinuing or adjusting the offending agent.